EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients

Cancer Treatment Reviews

Volumn 36, Issue 1, 2010, Pages 83-90

  Pallis, A G ^a   Papamichael, D ^b   Audisio, R ^c   Peeters, M ^d   Folprecht, G ^e   Lacombe, D ^a   Van Cutsem, E ^f  

^a EORTC DATA CENTER   (Belgium)

^b BOC Oncology Center   (Cyprus)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Age; Colon cancer; EORTC; Expert's opinion; Older

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; PANITUMUMAB;

CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; INFECTION; LAPAROSCOPIC SURGERY; LIFE EXPECTANCY; LIVER METASTASIS; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PROTEINURIA; QUALITY OF LIFE; REVIEW; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; WOUND HEALING;

AGE FACTORS; AGED; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COLONIC NEOPLASMS; GERIATRIC ASSESSMENT; HUMANS; RETROSPECTIVE STUDIES;

EID: 75049085080     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.10.008     Document Type: Review

References (81)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
2. Kohne C.H., Folprecht G., Goldberg R.M., Mitry E., and Rougier P. Chemotherapy in elderly patients with colorectal cancer. Oncologist 13 4 (2008) 390-402
3. Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer 36 14 (2000) 1741-1754
4. Bottomley A., Vanvoorden V., Flechtner H., and Therasse P. The challenges and achievements involved in implementing quality of life research in cancer clinical trials. Eur J Cancer 39 3 (2003) 275-285
5. Yellen S.B., Cella D.F., and Leslie W.T. Age and clinical decision making in oncology patients. J Natl Cancer Inst 86 23 (1994) 1766-1770
6. Balducci L., and Extermann M. Management of cancer in the older person: a practical approach. Oncologist 5 3 (2000) 224-237
7. Hutchins L.F., Unger J.M., Crowley J.J., Coltman Jr. C.A., and Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. New Engl J Med 341 27 (1999) 2061-2067
8. Lewis J.H., Kilgore M.L., Goldman D.P., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21 7 (2003) 1383-1389
9. Potosky A.L., Harlan L.C., Kaplan R.S., Johnson K.A., and Lynch C.F. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 20 5 (2002) 1192-1202
10. Balducci L. The geriatric cancer patient: equal benefit from equal treatment. Cancer Control 8 2 Suppl. (2001) 1-25
11. Townsley C.A., Selby R., and Siu L.L. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23 13 (2005) 3112-3124
12. Townsley C.A., Chan K.K., Pond G.R., Marquez C., Siu L.L., and Straus S.E. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer 6 (2006) 34
13. Basche M., Baron A., Eckhardt S.G., et al. Barriers to enrollment of elderly adults in early-phase cancer clinical trials. J Oncol Pract 4 4 (2008) 162-168
14. Surgery for colorectal cancer in elderly patients: a systematic review. Colorectal Cancer Collaborative Group. Lancet 2000;356(9234):968-74.
15. Tan E., Tilney H., Thompson M., Smith J., and Tekkis P.P. The United Kingdom National Bowel Cancer Project - epidemiology and surgical risk in the elderly. Eur J Cancer 43 15 (2007) 2285-2294
16. van Leeuwen B.L., Pahlman L., Gunnarsson U., Sjovall A., and Martling A. The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region. Crit Rev Oncol Hematol 67 3 (2008) 229-236
17. Ong E.S., Alassas M., Dunn K.B., and Rajput A. Colorectal cancer surgery in the elderly: acceptable morbidity?. Am J Surg 195 3 (2008) 344-348
18. Schiffmann L., Ozcan S., Schwarz F., Lange J., Prall F., and Klar E. Colorectal cancer in the elderly: surgical treatment and long-term survival. Int J Colorectal Dis 23 6 (2008) 601-610
19. Gurlich R., Maruna P., Kalvach Z., Peskova M., Cermak J., and Frasko R. Colon resection in elderly patients: comparison of data of a single surgical department with collective data from the Czech Republic. Arch Gerontol Geriatr 41 2 (2005) 183-190
20. Chiappa A., Zbar A.P., Bertani E., et al. Surgical treatment of advanced colorectal cancer in the elderly. Chir Ital 57 5 (2005) 589-596
21. Makela J.T., Kiviniemi H., and Laitinen S. Survival after operations for colorectal cancer in patients aged 75 years or over. Eur J Surg 166 6 (2000) 473-479
22. Basili G., Lorenzetti L., Biondi G., et al. Colorectal cancer in the elderly. Is there a role for safe and curative surgery?. ANZ J Surg 78 6 (2008) 466-470
23. Takeuchi K., Tsuzuki Y., Ando T., et al. Should patients over 85 years old be operated on for colorectal cancer?. J Clin Gastroenterol 38 5 (2004) 408-413
24. Louis D.J., Hsu A., Brand M.I., and Saclarides T.J. Morbidity and mortality in octogenarians and older undergoing major intestinal surgery. Dis Colon Rectum 52 1 (2009) 59-63
25. Gurevitch A.J., Davidovitch B., and Kashtan H. Outcome of right colectomy for cancer in octogenarians. J Gastrointest Surg 13 1 (2009) 100-104
26. Lee L., Jannapureddy M., Albo D., et al. Outcomes of Veterans affairs patients older than age 80 after surgical procedures for colon malignancies. Am J Surg 194 5 (2007) 646-651
27. Audisio R.A., Zbar A.P., and Jaklitsch M.T. Surgical management of oncogeriatric patients. J Clin Oncol 25 14 (2007) 1924-1929
28. Quaglia A., Capocaccia R., Micheli A., Carrani E., and Vercelli M. A wide difference in cancer survival between middle aged and elderly patients in Europe. Int J Cancer 120 10 (2007) 2196-2201
29. Audisio R.A., Pope D., Ramesh H.S., et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 65 2 (2008) 156-163
30. Slaets J.P. Vulnerability in the elderly: frailty. Med Clin North Am 90 4 (2006) 593-601
31. Alves A., Panis Y., Mathieu P., Mantion G., Kwiatkowski F., and Slim K. Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a prospective multicenter study. Arch Surg 140 3 (2005) 278-283 [discussion]
32. Janssen-Heijnen M.L., Maas H.A., Houterman S., Lemmens V.E., Rutten H.J., and Coebergh J.W. Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer 43 15 (2007) 2179-2193
33. Pope D., Ramesh H., Gennari R., et al. Pre-operative assessment of cancer in the elderly (PACE): a comprehensive assessment of underlying characteristics of elderly cancer patients prior to elective surgery. Surg Oncol 15 4 (2006) 189-197
34. Stocchi L., Nelson H., Young-Fadok T.M., Larson D.R., and Ilstrup D.M. Safety and advantages of laparoscopic vs. open colectomy in the elderly: matched-control study. Dis Colon Rectum 43 3 (2000) 326-332
35. Law W.L., Chu K.W., and Tung P.H. Laparoscopic colorectal resection: a safe option for elderly patients. J Am Coll Surg 195 6 (2002) 768-773
36. Senagore A.J., Madbouly K.M., Fazio V.W., Duepree H.J., Brady K.M., and Delaney C.P. Advantages of laparoscopic colectomy in older patients. Arch Surg 138 3 (2003) 252-256
37. Feng B., Zheng M.H., Mao Z.H., et al. Clinical advantages of laparoscopic colorectal cancer surgery in the elderly. Aging Clin Exp Res 18 3 (2006) 191-195
38. Fong Y., Fortner J., Sun R.L., Brennan M.F., and Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 3 (1999) 309-318
39. Zacharias T., Jaeck D., Oussoultzoglou E., Bachellier P., and Weber J.C. First and repeat resection of colorectal liver metastases in elderly patients. Ann Surg 240 5 (2004) 858-865
40. Mazzoni G., Tocchi A., Miccini M., et al. Surgical treatment of liver metastases from colorectal cancer in elderly patients. Int J Colorectal Dis 22 1 (2007) 77-83
41. Nojiri K., Nagano Y., Tanaka K., et al. Validity of hepatic resection of colorectal liver metastases in the elderly (75 years and older). Anticancer Res 29 2 (2009) 583-588
42. Mann C.D., Neal C.P., Pattenden C.J., et al. Major resection of hepatic colorectal liver metastases in elderly patients - an aggressive approach is justified. Eur J Surg Oncol 34 4 (2008) 428-432
43. Bockhorn M., Sotiropoulos G.C., Sgourakis G., et al. Major liver resections in the elderly - is an aggressive approach justified?. Int J Colorectal Dis 24 1 (2009) 83-86
44. de Liguori-Carino N., van Leeuwen B.L., Ghaneh P., Wu A., Audisio R.A., and Poston G.J. Liver resection for colorectal liver metastases in older patients. Crit Rev Oncol Hematol 67 3 (2008) 273-278
45. Figueras J., Ramos E., Lopez-Ben S., et al. Surgical treatment of liver metastases from colorectal carcinoma in elderly patients. When is it worthwhile?. Clin Transl Oncol 9 6 (2007) 392-400
46. Pallis A.G., and Mouzas I.A. Adjuvant chemotherapy for colon cancer. Anticancer Res 26 6C (2006) 4809-4815
47. Sundararajan V., Mitra N., Jacobson J.S., Grann V.R., Heitjan D.F., and Neugut A.I. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136 5 (2002) 349-357
48. Jessup J.M., Stewart A., Greene F.L., and Minsky B.D. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 294 21 (2005) 2703-2711
49. Neugut A.I., Matasar M., Wang X., et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 24 15 (2006) 2368-2375
50. Bouvier A.M., Jooste V., Bonnetain F., et al. Adjuvant treatments do not alter the quality of life in elderly patients with colorectal cancer: a population-based study. Cancer 113 4 (2008) 879-886
51. Fata F., Mirza A., Craig G., et al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center. Cancer 94 7 (2002) 1931-1938
52. Popescu R.A., Norman A., Ross P.J., Parikh B., and Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17 8 (1999) 2412-2418
53. Sargent D.J., Goldberg R.M., Jacobson S.D., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. New Engl J Med 345 15 (2001) 1091-1097
54. Quasar Collaborative Group, Gray R., Barnwell J., et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370 9604 (2007) 2020-2029
55. Twelves C., Wong A., Nowacki M.P., et al. Capecitabine as adjuvant treatment for stage III colon cancer. New Engl J Med 352 26 (2005) 2696-2704
56. Scheithauer W., McKendrick J., Begbie S., et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 14 12 (2003) 1735-1743
57. Lichtman S.M., Wildiers H., Chatelut E., et al. International society of geriatric oncology chemotherapy taskforce: evaluation of chemotherapy in older patients - an analysis of the medical literature. J Clin Oncol 25 14 (2007) 1832-1843
58. Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-FU/LV in stage III colon cancer: updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy. In: ASCO gastrointestinal cancers symposium; 2008 [abstr 274].
59. Field KM, Kosmider S, Desai J, Lim L, Barnett F, Gibbs P. Capecitabine in colorectal cancer: a five-year review of use in routine clinical care. In: ASCO gastrointestinal cancers symposium; 2009.
60. Goldberg R.M., Tabah-Fisch I., Bleiberg H., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24 25 (2006) 4085-4091
61. McCleary N.J., Meyerhardt J., Green E., et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 27 15s (2009) [abstr 4010]
62. Allegra C.J., Yothers G., O'Connell M.J., et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27 20 (2009) 3385-3390
63. Folprecht G., Cunningham D., Ross P., et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15 9 (2004) 1330-1338
64. Chiara S., Nobile M.T., Vincenti M., et al. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 42 4 (1998) 336-340
65. Cassidy J., Twelves C., Van Cutsem E., et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13 4 (2002) 566-575
66. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 9209 (2000) 1041-1047
67. Kohne C.H., van C.E., Wils J., et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23 22 (2005) 4856-4865
68. Mitry E., Douillard J.Y., Van C.E., et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 15 7 (2004) 1013-1017
69. Chau I., Norman A.R., Cunningham D., et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Brit J Cancer 91 8 (2004) 1453-1458
70. Folprecht G., Seymour M.T., Saltz L., et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2691 patients in randomized controlled trials. J Clin Oncol 26 9 (2008) 1443-1451
71. Figer A., Perez-Staub N., Carola E., et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 110 12 (2007) 2666-2671
72. Seymour M.T., Maughan T., Wasan H.S., et al. Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: the FOCUS2 trial. J Clin Oncol (2007) 25 [abstr 9030]
73. Mitry E, Phelip JM, Bonnetain F, et al. Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001-02 trial): results of a planned interim analysis. In; ASCO gastrointestinal cancers symposium; 2008 [abstr 281].
74. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 350 23 (2004) 2335-2342
75. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 16 (2007) 1232-1239
76. Kabbinavar F.F., Hurwitz H.I., Yi J., Sarkar S., and Rosen O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 27 2 (2009) 199-205
77. Grothey A., Sugrue M.M., Purdie D.M., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26 33 (2008) 5326-5334
78. Kozloff M., Sugrue M.M., Purdie D.M., et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study. J Clin Oncol (2008) [abstr 4026]
79. Van C.E., Rivera F., Berry S., et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol (2009) [April 30]
80. Van Cutsem E., Rivera F., Berry S., et al. Safety and efficacy of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: results from the BEAT observational cohort study. Ann Oncol 20 Suppl. 7 (2009) PD-0005
81. Bouchahda M., Macarulla T., Spano J.P., et al. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol 67 3 (2008) 255-262